{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:40:27Z","timestamp":1792672827954,"version":"4.5.0"},"reference-count":24,"publisher":"Media Sphere Publishing House","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["S.S. Korsakov J. Neuro. Psych."],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:p>Absence epilepsy is a common form of pseudo-remission, in which patients and observers may incorrectly believe seizures have ceased while paroxysms persist in subtle form. Three primary factors contribute to this phenomenon: the brief duration (typically less than 10 seconds) and indistinct semiology of typical absences; the limited reliability of parental observation (sensitivity up to 43%); and the occurrence of generalized spike-wave discharges without significant clinical manifestations, which are nonetheless associated with fluctuations in wakefulness. Verification of remission requires at least a properly conducted three-minute hyperventilation test with attentional load. Preferred methods for objective assessment include prolonged video-EEG monitoring that registers wakefulness, sleep, and arousal, and, when indicated, intermittent photic stimulation. However, no direct comparative studies have demonstrated superiority of these methods over short-term EEG with adequately performed hyperventilation. Extended EEG monitoring does not substitute for the induction of provoking factors, and functional testing does not obviate the need for sufficient recording duration. The absence of \u201cpeak-slow wave\u201d discharges lasting three seconds or longer may serve as a practical operational criterion, as adopted from the CAE study protocol. Data are presented on the proportion of patients free from treatment failure with ethosuximide, valproic acid, and lamotrigine in patients with newly diagnosed childhood absence epilepsy at Week 16 (53%, 58%, and 29%, respectively) and at Month 12 (45%, 44%, and 21%, respectively). The review also describes the mechanism of action of ethosuximide, discrepancies between NICE recommendations and Russian clinical guidelines, dosing considerations, and the need for laboratory monitoring. The clinical benefit of adjusting therapy based on EEG findings in patients with apparent clinical well-being remains unproven.<\/jats:p>","DOI":"10.17116\/jnevro202612609289","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:37:40Z","timestamp":1792669060000},"page":"89","source":"Crossref","is-referenced-by-count":0,"special_numbering":"Vyp. 2","title":["Pseudo-remission in childhood absence epilepsy. Objective assessment of seizure control and the role of ethosuximide"],"prefix":"10.17116","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7231-0249","authenticated-orcid":false,"given":"N.V.","family":"Chebanenko","sequence":"first","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4844-8042","authenticated-orcid":false,"given":"M.B.","family":"Mironov","sequence":"additional","affiliation":[{"name":"LLC Neuromozaika Medical Center","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-6160","authenticated-orcid":false,"given":"V.A.","family":"Egorov","sequence":"additional","affiliation":[{"name":"National Medical Research Center for Therapy and Preventive Medicine","place":["Moscow, Russia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6743","reference":[{"key":"key-10.17116\/jnevro202612609289-1","unstructured":"Mironov MB, Burd SG, Krasil\u2019shchikova TM, et al. The state of apparent well-being in epilepsy. A clinical case of a patient with juvenile myoclonic epilepsy. Meditsinskii alfavit. 2017;3(33):18-20. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609289-2","unstructured":"Mironov MB, Mukhin KYu, Petrukhin AS, Kholin AA. Monitoring the effectiveness of treatment in patients with juvenile forms of idiopathic generalized epilepsy and the state of \u201cpseudoremission\u201d. S.S. Korsakov Journal of Neurology and Psychiatry. 2005;105(8):24-28. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609289-3","unstructured":"Mironov MB. Analysis of the main causes of misdiagnosis of epileptic seizures and epileptic syndromes (clinical features of epileptic seizures). Russkii zhurnal detskoi nevrologii. 2014;9(4):40-48. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609289-4","unstructured":"Mironov MB. Epileptic eyelid myoclonus (lecture). Russkii Zhurnal Detskoi Nevrologii. 2010;5(4):29-38. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609289-5","doi-asserted-by":"publisher","DOI":"10.17650\/2073-8803-2015-10-2-6-12"},{"key":"key-10.17116\/jnevro202612609289-6","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17236"},{"key":"key-10.17116\/jnevro202612609289-7","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000228257.60184.82"},{"key":"key-10.17116\/jnevro202612609289-8","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2009.05.009"},{"key":"key-10.17116\/jnevro202612609289-9","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00584-2"},{"key":"key-10.17116\/jnevro202612609289-10","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-019-09419-2"},{"key":"key-10.17116\/jnevro202612609289-11","unstructured":"Mironov MB, Okuneva IV, Mukhin KYu. The state of apparent deterioration in epilepsy. Russkii Zhurnal Detskoi Nevrologii. 2014;9(1):23-27. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609289-12","doi-asserted-by":"publisher","DOI":"10.1177\/08830738241273347"},{"key":"key-10.17116\/jnevro202612609289-13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902014"},{"key":"key-10.17116\/jnevro202612609289-14","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.18-13-04842.1998"},{"key":"key-10.17116\/jnevro202612609289-15","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa072"},{"key":"key-10.17116\/jnevro202612609289-16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12028"},{"key":"key-10.17116\/jnevro202612609289-17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003032.pub5"},{"key":"key-10.17116\/jnevro202612609289-18","unstructured":"National Institute for Health and Care Excellence. Epilepsies in children, young people and adults. NICE guideline NG217. London: NICE; 2022. Last reviewed November 25, 2025. Accessed August 17, 2026. https:\/\/www.nice.org.uk\/guidance\/ng217"},{"key":"key-10.17116\/jnevro202612609289-19","unstructured":"Clinical guidelines \u201cEpilepsy and status epilepticus in adults and children\u201d. Ministry of Health of the Russian Federation; 2022. Identifier: 741. (In Russ.). https:\/\/cr.minzdrav.gov.ru\/schema\/741_1"},{"key":"key-10.17116\/jnevro202612609289-20","unstructured":"State Register of Medicines of the Russian Federation. Marketing authorizations LP-005317, LP-N(002369)-(RG-RU), LP-008832 (ethosuximide). (In Russ.). https:\/\/grls.rosminzdrav.ru"},{"key":"key-10.17116\/jnevro202612609289-21","unstructured":"Instructions for medical use of ethosuximide, 250 mg capsules. Marketing authorization No. LP-008832 dated October 25, 2023. (In Russ.)"},{"key":"key-10.17116\/jnevro202612609289-22","unstructured":"Emeside 250 mg\/5 ml Syrup (ethosuximide). Summary of Product Characteristics. Essential Pharma Ltd. Electronic Medicines Compendium. Accessed August 17, 2026.  https:\/\/www.medicines.org.uk\/emc\/product\/13121\/smpc"},{"key":"key-10.17116\/jnevro202612609289-23","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2965"},{"key":"key-10.17116\/jnevro202612609289-24","unstructured":"Mironov MB, Mukhin KYu. Atypical absences: prevalence, electroclinical and neuroimaging characteristics. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(6-2):18-26. (In Russ.)"}],"container-title":["S.S. Korsakov Journal of Neurology and Psychiatry"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:38:10Z","timestamp":1792669090000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova-2\/2026\/9-2\/1199772982026092089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,10,22]]}},"alternative-id":["10.17116\/jnevro202612609289"],"URL":"https:\/\/doi.org\/10.17116\/jnevro202612609289","relation":{},"ISSN":["1997-7298"],"issn-type":[{"value":"1997-7298","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10,22]]}}}